Autologous Muscle Derived Cells for Female Urinary Sphincter Repair
A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Stress Urinary Incontinence
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium, 3000
- University Hospital Leuven
-
-
-
-
-
Essen, Germany, 45147
- Universitätsklinikum Essen
-
Mülheim, Germany, 45468
- Praxisklinik Urologie Rhein-Ruhr (PUR/R)
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Mayo Clinic Arizona Phoenix Campus
-
-
California
-
Agoura Hills, California, United States, 91301
- The American Association of Female Pelvic Medicine Specialists
-
Los Angeles, California, United States, 90024
- Ronald Reagan UCLA Medical Center
-
Stanford, California, United States, 94304
- Stanford University
-
-
Florida
-
Weston, Florida, United States, 33331
- Cleveland Clinic Florida
-
-
Georgia
-
Atlanta, Georgia, United States, 30033
- Emory University
-
-
Illinois
-
Skokie, Illinois, United States, 60076
- Northshore University Healthsystem
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- IU Health Physicians Urogynecology
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49503
- Female Pelvic Medicine & Urogynecology Institute of Michigan
-
Grand Rapids, Michigan, United States, 49503
- Mercy Health Saint Mary's Campus
-
Royal Oak, Michigan, United States, 48073
- William Beaumont Hospital
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center
-
New York, New York, United States, 10016
- NYU Urology Associates
-
Poughkeepsie, New York, United States, 12601
- Premier Medical Group of the Hudson Valley PC
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
- McKay Urology
-
-
Ohio
-
Cincinnati, Ohio, United States, 45242
- The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma Health Sciences Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
Greenville, South Carolina, United States, 29607
- Greenville Health System
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57105
- Sanford Female Pelvic Medicine and Reconstructive Surgery Clinic
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Methodist Urology Associates
-
-
Virginia
-
Falls Church, Virginia, United States, 22042
- INOVA Fairfax Hospital
-
-
Washington
-
Seattle, Washington, United States, 98101
- Benaroya Research Institute at Virginia Mason
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female patient has primary symptoms of SUI, as confirmed by patient medical history and clinical symptoms, including a focused incontinence evaluation.
Exclusion Criteria:
- Patient has symptoms of pure urge incontinence as confirmed by basic evaluation of etiology from a patient medical history, including a focused incontinence history.
- Patient has symptoms of mixed urinary incontinence where urge incontinence is the predominant factor.
- Patient has had stress urinary incontinence symptoms less than 6 months prior to signing the informed consent.
- Patient has not previously attempted conservative treatment prior to signing the informed consent. (Examples of conservative treatment include behavior modifications, bladder exercises, biofeedback, etc.)
- Patient has more than 2 episode of awakening to void during normal sleeping hours.
- Patient cannot be maintained on a stable dose and/or frequency of medication (including diuretics) known to affect lower urinary tract function, including but not limited to, anticholinergics, tricyclic antidepressants or alpha-adrenergic blockers, for at least 2 weeks prior to screening or is likely to change during the course of the study.
- Patient is pregnant, lactating, or plans to become pregnant during the course of the study.
- Patient refuses to provide written informed consent.
- Patient is not at least 18 years of age.
- Patient is not available for the follow-up evaluations as required by the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Placebo control is the vehicle solution used for the study product.
|
Placebo control is the vehicle solution used for the study product.
|
|
Experimental: Iltamiocel
AMDC is the study product (autologous muscle-derived cells).
The generic name is iltamiocel.
Single intraurethral injection of 150 x 10^6 cells.
|
AMDC is the study product (autologous muscle-derived cells).
The generic name is iltamiocel.
Single intraurethral injection of 150 x 10^6 cells.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Participants With ≥ 50% Reduction in Stress Incontinence Episode Frequency From Baseline to 12 Months Post-treatment; as Assessed by 3 Day Diary
Time Frame: Baseline and 12 months
|
Baseline and 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Participants With at ≥ 75% Reduction in Stress Incontinence Episodes From Baseline at 12 Months
Time Frame: Baseline and 12 months
|
Baseline and 12 months
|
|
Participants With 0 or 1 Stress Incontinence Episodes Based on 3 Day Diary Records at 12 Months
Time Frame: Baseline and 12 months
|
Baseline and 12 months
|
|
Change in the Frequency of Stress Incontinence Episodes From Baseline at 12 Months
Time Frame: Baseline and 12 months
|
Baseline and 12 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Association of Change in Quality of Life Scores With Change in Stress Incontinence Episode Frequency
Time Frame: Baseline and 12 months
|
Spearman's correlation used for analysis
|
Baseline and 12 months
|
|
Treatment Durability at 24 Months
Time Frame: Baseline, 12 months, and 24 months after injection with iltamiocel
|
Treatment durability defined as iltamiocel-treated participants with reduction in stress incontinence episode frequency (SIEF) at 12 months who maintained that response at 24 months
|
Baseline, 12 months, and 24 months after injection with iltamiocel
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 13-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.